Oncotype DX®, developed by Genomic Health®, is a diagnostic test that quantifies the likelihood of disease recurrence in women with early-stage hormone estrogen receptor (ER) positive only breast cancer (prognostic significance) and assesses the likely benefit from certain types of chemotherapy (predictive significance).
|Name||Oncotype DX ®|
|Description||Oncotype DX® is a diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX® also assesses the benefit from certain types of chemotherapy. The assay-performed using formalin-fixed, paraffin-embedded tumor tissue-analyses the expression of a panel of 21 genes and the results are provided as a Recurrence Score™ (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies.|
CLIA- Certified (Clinical Laboratory Improvement Amendments of 1988)
CAP-accredited reference laboratory
|Business Partner||Genomic Health, Inc.|